Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 28 symbols : PFE save search
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
potential license hiv
Epileptic Seizures Treatment Market is expected to Cross US$ 1.77 Billion by 2030 End, Says TMR
Published: 2021-09-28 (Crawled : 12:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
treatment
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.15%
H: 0.06%
C: -0.6%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -4.36%
H: 1.09%
C: -5.85%
covid fda children vaccine trial
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.73%
H: 0.13%
C: -0.44%
new drug fda drug hiv application granted grant
Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Published: 2021-09-28 (Crawled : 06:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.15%
H: 0.49%
C: -0.07%
disease phase 2 positive phase 2 results results vaccine response
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
OUST 4 | $7.16 2.43% 3.77% 880K
|
Manufacturing
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
DDL | News | $1.15 6.48% 3.48% 200K
|
Retail Trade
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
LEV | $0.972 0.73% 2.88% 570K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.